VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors

(2015) Shinji Nakamichi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

(2015) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy

(2013) Roberto Iacovelli et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour

(2013) Y.-f. Shea et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations

(2013) Patricia A. Tang et al.   Therapeutic Advances in Gastroenterology

Development and strategies of VEGFR-2/KDR inhibitors

(2012) Lingyi Huang et al.   Future Medicinal Chemistry

Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases

(2012) M. Shibuya   JOURNAL OF BIOCHEMISTRY

Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors

(2012) Francesca Musumeci et al.   JOURNAL OF MEDICINAL CHEMISTRY

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

(2012) Jeffrey S. Heier et al.   OPHTHALMOLOGY

Sunitinib-induced hyperparathyroidism

(2011) Valentina Baldazzi et al.   CANCER

Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability

(2011) Jun Ge et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Fatal Heart Failure After a 26-Month Combination of Tyrosine Kinase Inhibitors in a Papillary Thyroid Cancer

(2011) Marie-Elisabeth Toubert et al.   THYROID

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers

(2010) N. R. Smith et al.   CLINICAL CANCER RESEARCH

Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib

(2010) G. Maarten-Friso Ruinemans et al.   LUNG CANCER

Human Studies of Angiogenic Gene Therapy

(2009) Rajesh Gupta et al.   CIRCULATION RESEARCH

Structure and function of VEGF receptors

(2009) Edward Stuttfeld et al.   IUBMB LIFE

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

An overview of small-molecule inhibitors of VEGFR signaling

(2009) S. Percy Ivy et al.   Nature Reviews Clinical Oncology

Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma

(2009) Vincent Launay-Vacher et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

VEGF receptor protein–tyrosine kinases: Structure and regulation

(2008) Robert Roskoski   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS